The aim of our company’s development work is to consolidate the use of new vaccine technology in Finland. At the heart of our product development is currently the second-generation coronavirus vaccine FINCoVac 2.0, which aims to obtain strong protection against the current variants of the coronavirus.
FINCoVac 2.0 Intranasal adenovirus vectored COVID-19 vaccine against current variants of concern
FINCoVac 2.1 Intranasal adenovirus vectored COVID-19 vaccine against emerging variants
The mutation of the SARS-CoV-2 virus to evade the immune system is likely to continue at a rapid pace and new variant outbreaks may be expected. The FINCoVac 2.0 vaccine already takes into account the most important ones of the current coronavirus variants, and the FINCoVac 2.1 vaccine is designed to meet the challenge of the future variants. Our aim is that in the future, our vaccines could be an easy-to-dose booster for those who are already fully vaccinated with other coronavirus vaccine(s). The same vaccine technology can also enable the development of new vaccines against other viruses.
Our goal is to start the first clinical trial with the FINCoVac 2.0 vaccine in Finland during summer 2022. At that time, healthy adult volunteers who are already fully vaccinated with other coronavirus vaccine(s) will be invited to participate in the clinical trial. After Phase I clinical trial, the next broader trial, Phase II, will be commenced, depending on the results of the previous phase. Similarly, an even wider Phase III clinical trial will then follow, depending on the results of the previous phases.
For legal reasons, recruitment of volunteer subjects may only begin once we have been granted trial authorisation from the authorities. Unfortunately, we are unable to receive volunteer enrolments in advance. We will provide more information about our clinical trials and their participation closer to the start of the trials.
Rokote Laboratories Finland Oy Y-Tunnus: 3155372-4 VAT: FI31553724